跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2021-001713-37-IT
EUCTR2021-001713-37-IT进行中（未招募）1 期

Phase II, two-cohorts, randomized trial comparing standard of care versus immune-based combination in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab - CONDOR

FONDAZIONE RICERCA TRASLAZIONALE (FORT)0 个研究点目标入组 176 人开始时间: 2021年10月18日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
发起方
入组人数
176
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •Inclusion Criteria:
  • •1.Body weight >30kg
  • •2.Recurrent or metastatic NSCLC relapsed during or after completion of chemoradiotherapy with curative intent and maintenance durvalumab for stage III disease. Patients are eligible if they receive at least two cycles of platinum based chemotherapy or radical radiotherapy
  • •3.Tumor tissue available for biomarker testing.
  • •4.Evidence of disease progression during durvalumab maintenance or at the end of planned treatment. Patients who have interrupted planned durvalumab treatment after at least 6 months for reasons other than toxicity or progression (e.g. patient’s choice, logistic reasons, intercurrent acute illnesses) are eligible. Patients progressing during the first three months of Durvalumab are not eligible
  • •5.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • •6.Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
  • •7.Age >18 years at time of study entry
  • •8.Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
  • •9.Life expectancy of at least 16 weeks
  • •10.Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below::
  • •¿Haemoglobin =10.0 g/dL with no blood transfusion in the past 28 days
  • •¿Absolute neutrophil count (ANC) =1.5 × 109 /L
  • •¿Platelet count =100 × 109/L
  • •¿Serum bilirubin =1.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.
  • •¿AST (SGOT)/ALT (SGPT) =2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =5x ULN
  • •¿creatinine clearance estimated of =51 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test:
  • •Creatinine CL (mL/min)=Weight (kg) x (140 – Age)
  • •72 x serum creatinine (mg/dL)
  • •Creatinine CL (mL/min)=Weight (kg) x (140 – Age)x 0.85 72 x serum creatinine (mg/dL)
  • •11.Female patients should be using adequate contraceptive measures (highly effective method of contraception are present in table 3 of protocol Highly Effective Methods of Contraception (<1% Failure Rate)”), should not be breastfeeding, from the time of screening throughout the total duration of the drug treatment and the drug washout period (90 days after the last dose of durvalumab monotherapy) or for at least 1 month after last dose of olaparib, or they must totally/truly abstain from any form of sexual intercourse. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal.
  • •12.Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1.
  • •13.Male patients must use a condo

排除标准

  • •1.No evidence of disease progression
  • •2.Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
  • •3.Patients not pretreated with durvalumab with curative intent
  • •4.Patients treated with non-radical radiotherapy or with non conventional radiotherapy
  • •5.More than 4 cycles of platinum-based chemotherapy
  • •6.Rapid progressors. Progressors within first 3 month of treatment will be excluded from this trial
  • •7.Any clinical reason that makes the patient ineligible to receive any investigator’s choice single-agent chemotherapy regimen (for patients enrolled in cohorts A and B)
  • •8.Any clinical reason that makes the patient ineligible to receive any investigator’s choice platinum-based doublet chemotherapy regimen (for patients enrolled in cohorts C and D)
  • •9.Persistent toxicities (>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia.
  • •10.Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML.
  • •11.Disease progression within the first three months of Durvalumab therapy
  • •12.Tumor tissue not available
  • •13.Evidence of EGFR mutations or ALK or ROS1 rearrangements
  • •14.Performance status >1 (ECOG)
  • •15.Brain metastases are allowed if asymptomatic and pretreated.
  • •16.Diagnosis of another cancer in the last 3 years, except for in situ carcinoma of cervix, breast and bladder or skin carcinoma (
  • •17.Patient with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days prior to enrolment..
  • •18.Leptomeningeal disease.
  • •19.Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (, or patients with congenital long QT syndrome.
  • •20.Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters (e.g., PleurX) are allowed.
  • •21.Malignancies other than NSCLC within 5 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS> 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent, grade 1 endometrial carcinoma)
  • •22.History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins and patient with a known hypersensitivity to olaparib or any of the excipient of the product.
  • •23.Known hypersensitivity or allergy to any component of the Durvalumab formulation
  • •24.History of autoimmune disease
  • •25.Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
  • •26.Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  • •27.History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • •28.Positive test for

研究者

发起方
FONDAZIONE RICERCA TRASLAZIONALE (FORT)

相似试验

进行中（未招募）
不适用
Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) - Vinorelbine + Cisplatin +/- Nitroglycerin in NSCLCSCLC (Non-small Cell Lung Cancer) stage IIIB/IVMedDRA version: 13.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2007-001262-32-DEGMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
进行中（未招募）
1 期
Prospective, phase II randomized study to compare busulfan-fludarabine reduced-intensity conditioning (RIC) with thiotepa-fludarabine RIC regimen prior to allogeneic transplantation of hematopoietic cells for the treatment of myelofibrosis
EUCTR2010-022052-23-ITGITMO GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO,CELLULE STAMINALI EMOPOIETICHE E TERAPIA CELLULARE - ONLUS60
招募中
2 期
A randomized controlled phase 2 trial comparing the safety and usefulness of robot-assisted esophagectomy and thoracoscopic
JPRN-jRCT1040220153Takeuchi Hiroya90
进行中（未招募）
1 期
A randomized comparative phase II trial evaluating the capacity of the dualcombination doravirine/raltegravir to maintain virological success in HIV-1infected patients with an HIV-RNA plasma viremia below 50 copies/mL under acurrent antiretroviral regimen.HIV-1 INFECTION
EUCTR2019-004195-19-ITCentre de Recherche et d’Etudes sur la Pathologie Tropical et le Sida (CREPATS)150
进行中（未招募）
1 期
A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma viremia below 50 copies/mL under a current antiretroviral regime
EUCTR2019-004195-19-FRCentre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida (CREPATS)150